SAVE THE DATE!!! 🧠
Our next webinar will be a journal club - "Early Blood Pressure Targets in Acute Spinal Cord Injury: A Randomized Clinical Trial "
Thursday, June 18, 3PM CST - Zoom link to be posted on Connect.
#SCCMNeuro#NeuroICU#NeuroX#NeuroTwitter
"We suggest that either prophylactic ASM or no ASM be used for seizure prophylaxis in patients undergoing supratentorial neurosurgery. If an ASM is used, we suggest LEV over PHT for a short duration."🧠
https://t.co/Cmiego4iHM
#SCCMNeuro#NeuroICU#NeuroX#NeuroTwitter
How did ANA Investigates become a leading voice in academic neurology?🎙️🧠
Host & new Executive Producer Dr. @ifrahzawar is joined by Drs. Adeline Goss, Megan Richie, and Romer Geocadin to reflect on the podcast’s origins and evolution since 2019.
🎧 https://t.co/ithyDO7dKd
Among patients with stroke due to medium-vessel occlusion, thrombectomy led to functional independence at 90 days (in 58.6% of patients, vs. 46.6% with medical management) but also to a higher risk of intracranial hemorrhage. Full ORIENTAL-MeVO trial results: https://t.co/FvyLPQz4CV
Editorial: Endovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Population https://t.co/hnLi0DvzuF
Hematoma evacuation efficacy may mediate the association between mean hematoma density and in-hospital mortality in pts w/ ICH undergoing minimally invasive surgery.🧠
https://t.co/MDEB7qOOWx
#SCCMNeuro#NeuroICU#NeuroX#NeuroTwitter
Deeply appreciate the work of my co-authors and AHA staff. We very much hope that the information we present is helpful towards achieving equitable stroke functional outcomes for all. 🙏 @StrokeAHA_ASA@TuftsMCNeuro
Sustained improvements in stroke recovery and secondary prevention depend on organizational capacity, equitable implementation based on need, and supportive community and policy infrastructure. Without these broader supports, patient-level interventions are unlikely to be effective or lasting
✍🏼 @senelson13@MonaBahouth@hayman_ll
🚨 #ESOC2026 Late-breaking: The LATE-MT trial shows improved 90-day outcomes in patients with large vessel occlusion (LVO) treated with EVT between 24–72 hours after stroke onset.
@ESOstroke#Stroke#EVT#Thrombectomy#LVO
🚨 The ATTRACTION trial at #ESOC2026 shows adjunct tirofiban after successful thrombectomy improves outcomes in acute ischaemic stroke.
✅ 49.3% vs 43.3% functional independence (90 days)
📈 Significant benefit (RR 1.15; p=0.01)
🧠 No increase in sICH or mortality
@ESOstroke
ATLAS meta-analysis of 6 trials on EVT for large core infarcts confirms large treatment effect of EVT, reducing disability and mortality, with a NNT of 4,2.
Treatment benefit was consistent over clinical and most imaging subgroups.
@ESOstroke#VoiceOfStroke#Stroke#ESOC2026
🚨 New #ESOC2026 trial results
Early administration of tirofiban after insufficient response to IV thrombolysis improved 90-day functional outcomes in acute ischemic stroke patients without increasing symptomatic ICH or mortality.
#Stroke#AcuteStroke#Thrombolysis@ESOstroke
SAVE THE DATE!!!🧠
Our next monthly Neuroscience Webinar will be on Thursday, May 21, 3-4PM CST:
"Leading Early, Rising Wisely: Leadership and the Art of Gentle Self-Promotion for Early Career Neurointensivists"
Zoom info on Connect.
#SCCMNeuro#NeuroICU#NeuroX#NeuroTwitter
Today, Laura C. Duncan and I had the opportunity to visit the Framingham practice. A highlight for me was hand-delivering a card signed by Dr. Erika Werner and Dr. Helen Boucher to Dr. Flavia Machado in recognition of her outstanding outpatient clinical care. @TuftsMCNeuro
What is the true financial value of an academic neurologist? 📊🧠
Join us on Friday, May 8, 5–6 PM EDT for a live webinar exploring RVUs, compensation trends, and the broader impact of academic neurology.
🔗 Register Now: https://t.co/TnxPuFHt8m
This retrospective observational study found that in patients receiving mechanical thrombectomy for large vessel occlusion #stroke, blood pressure drops during the first 24 hours after groin puncture are common and associated with worse functional outcome: https://t.co/0vMB1YINHt
Among survivors of intracerebral hemorrhage, a single pill with three low-dose antihypertensive agents added to standard care was associated with a lower incidence of stroke and major cardiovascular events than placebo. Full TRIDENT trial results: https://t.co/0tiij1H7tb
Editorial: Blood-Pressure Control after Intracerebral Hemorrhage — An Unbroken Glass Ceiling https://t.co/Me1YWely2x
Is iNPH a distinct clinical syndrome—or still an open question in neurology? 🧠💧
Drs. Alberto Espay & Michael Williams join Dr. Kara Wyant in ANA Investigates to unpack diagnosis, management, & ongoing debates, along with insights from the PENS trial.
🎧 https://t.co/9Q1qbBx2EU
Our new paper in Neurocritical Care presents the first TeleNCC Consensus Statement—defining best practice, minimum standards, and benchmarks for teleneurocritical care.
Here are the key takeaways 👇
#TeleNCC#NeurocriticalCare#Stroke@Intermountain https://t.co/bbYGPYB9Ki
In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: https://t.co/UPJGedYXFe
Editorial: Asundexian for Noncardioembolic Ischemic Stroke https://t.co/V1dVNbx4T8
Study in @JAMANeuro co-authored by Tufts Medicine + @TuftsMedSchool neurologists: PASCAL system identifies stroke patients who benefit from PFO closure.
Learn more: https://t.co/FzgOH8ekee